Recent advances in the chemistry of phthalimide analogues and their therapeutic potential

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 8, 2010, Pages 678-704

  Sharma, U ^a   Kumar, P ^a   Kumar, N ^a   Singh, B ^a  

^a CSIR INSTITUTE OF HIMALAYAN BIORESOURCE TECHNOLOGY   (India)

Author keywords

Anti angiogenesis; Anti cancerous; Anti inflammatory; Peripheral analgesic; Phthalimide; Polyamide; Structure activity relationship; TNF

Indexed keywords

4 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL) N (2,6 DIMETHYLPHENYL)BUTANAMIDE; IONIC LIQUID; PHTHALIC ANHYDRIDE; PHTHALIMIDE DERIVATIVE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

ANALGESIC ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; MICROWAVE RADIATION; NONHUMAN; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CHEMISTRY; METABOLISM; SYNTHESIS;

ANALGESICS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOLOGIC FACTORS; PHTHALIMIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954734487     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791572442     Document Type: Article

References (83)

1. Gabriel, S. On a representation of primary amines from the corresponding halogen compounds. Chem. Ber., 1887, 20, 2224-2236.
2. Lima, L. M.; Castro, P.; Machado, A. L.; Fraga, C. A. M.; Lugniur, C.; Moraes, V. L. G.; Barreiro, E. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. J. Biol. Org. Med. Chem., 2002, 10, 3067-3073.
3. Orzeszka, A.; Kaminsaka, B.; Orzesko, G.; Stareerciak, J. Synthesis and antimicrobial activity of new adamantane derivatives II. II Farmaco., 2000, 55, 619.
4. Siadak, K.; Sullivan, K. M. The management of chronic graftversus-host disease. Blood Rev., 1994, 8, 154-160.
5. Wallach, D. Suicide by order: Some open questions about the cellkilling activities of the TNF ligand and receptor families. Cytokine Growth Factor Rev., 1996, 7, 211-221.
6. Pasparakis, M.; Alexopoulou, L.; Douni, E.; Kollias, G. Tumour necrosis factors in immune regulation: everything that's interesting is new! Cytokine Growth Factor Rev., 1996, 7, 223-229.
7. Carswell, E. A.; Old, L. J.; Kassel, R. L.; Green, S.; Foire, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 3666-3670.
8. Siadak, K.; Sullivan, K. M. The management of chronic graftversus-host disease. Blood Rev., 1994, 8, 154-160.
9. Smith, C. A.; Farrah, T.; Goodwin, R. G. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell, 1994, 76, 959-962.
10. Debs, R. J.; Fuchs, H. J.; Philip, R.; Brunette, E. N.; Duzgunes, N.; Shellito, J. E.; Kiggit, D.; Patton, J. R. Immunomodulatory and Toxic Effects of Free and Liposome-encapsulated Tumor Necrosis Factor α in Rats. Cancer Res., 1990, 50, 375-380.
11. Boussiotis, V. A.; Nadlar, L. M.; Strominger, J. L.; Goldfield, A. E. Tumor Necrosis Factor Alpha is an Autocrine Growth Factor for Normal Human B Cells.Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 7007-7011.
12. Manda, T.; Nishigaki, F.; Mori, J.; Shimomura, K. Important Role of Serotonin in the Antitumor Effects of Recombinant Human Tumor Necrosis Factor-α in Mice. Cancer Res., 1988, 48, 4250-4255.
13. Komori, A.; Suganuma, M.; Okabe, S.; Zou, X.; Tius, M. A.; Fujiki, H. Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factor α release and of protein isoprenylation. Cancer Res., 1993, 53, 3462-3464.
14. Makonkawkeyoon, S.; Limon-Pombre, R. N. R.; Moreira, A. L.; Schauf, V.; Kaplan, G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 5974-5978.
15. Hotamisligil, G. S.; Spiegelman, B. H. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 1994, 43, 1271-1278.
16. Shibata, Y.; Sasaki, K.; Hashimoto, Y.; Iwasaki, S. Tumor necrosis factor alpha production enhancers with a phenylphthalimide skeleton. Biochem. Biophys. Res. Commun., 1994, 205, 1992-1997.
17. Perker, P. M.; Chao, N.; Nademanee, A.; O'Donnell, M.; Schmidt, G. M.; Snyder, D. S.; Stein, A. S.; Smith, E. P.; Molina, A.; Stepan, D. E.; Kashyap, A.; Planas, I.; Spielberger, R.; Somlo, G.; Margolin, K.; Zwingenberger, K.; Wilsman, K.; Negrin, R. S.; Long, G.; Niland, J. C.; Blume, K. G.; Forman, S. J. Blood, 1995, 86, 3604.
18. Atra, E.; Sato, E. I. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin. Exp. Rheumatol., 1993, 11, 487-493.
19. Ochonisky, S.; Verroust, J.; Bastuji-Garin, S.; Gherardi, R.; Revuz, J. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch. Dermatol., 1994, 130, 66-69.
20. Sampio, E. P.; Sarno, E. N.; Galilly, R.; Cohn, Z. A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., 1991, 173, 699-703.
21. Miyachi, H.; Azuma, A.; Hioki, E.; Iwasaki, S.; Kobayashi, Y.; Hashimoto, Y. Inducer-specific bidirectional regulation by thalidomide and phe-nylphthalimides of tumor necrosis factor-alpha production. Biochem. Biophys. Res. Commun., 1996, 224, 426-430.
22. Miyachi, H.; Azuma, A.; Ogasawara, A.; Uchimura, E.; Watanabe, N.; Kobayashi, Y.; Kato, F.; Kato, M. Novel biological response modifiers: phthalimides with tumor necrosis factor-α production regulating activity. J. Med. Chem., 1997, 40 (18), 2858-2865.
23. Shibata, Y.; Shichita, M.; Sasaki, K.; Nishimoto, K.; Hashimoto, Y.; Iwasaki, S. N-alkylphthalimides: structural requirement of thalidomidal action on 12-0-tetradecanoylphorbol-13-acetate-induced tumor necrosis α factor production by human leukemia hl-60 cells. Chem. Pharma. Bull., 1995, 43(1), 177-179.
24. Miyachi, H.; Azuma, A.; Hioki, E.; Kobayashi, Y.; Iwasaki, S.; Hashimato, Y. Inducer-specific regulators of tumor necrosis factor alpha production. Chem. Pharma. Bull., 1996, 44(10), 1980-1982.
25. Shibata, Y.; Sasaki, K.; Nishimoto, K.; Hashimoto, Y.; Iwasaki, S. Phenylphthalimides with tumor necrosis factor alpha production enhancing activity. Chem. Pharma Bull., 1996, 44(1), 156-162.
26. Mallakpour, S. E.; Hajipour, A.; Mahdavian, A.; Khoee, S. Synthesis and characterization of novel optically active and flameretardant heterocyclic polyimides. J. Appl. Polym. Sci., 2000, 76, 240-248.
27. Liaw, D. J.; Hsu, P. N.; Chen, J. J.; Liaw, B. Y.; Hwang, C. Y. Synthesis and characterization of new soluble polyamides containing phthalimide pendent group. J. Polym. Sci. Part A: Polym. Chem., 2001, 39, 1557-1563.
28. Liaw, D. J.; Tsai, C. H. Synthesis and characterization of poly(norbornene) substituted with phthalimide and ammonium groups via living ring-opening metathesis polymerization. J. Mol. Catalysis A., 1999, 147, 23-31.
29. Miyachi, H.; Azuma, A.; Kitamoto, T.; Hayashi, K.; Kato, S.; Koga, M.; Sato, B.; Hashimoto, Y. Potent novel nonsteroidal androgen antagonists with a phthalimide skeleton. Bioorg. Med. Chem. Lett., 1997, 7, 1483-1488.
30. Tucker, H.; Crook, J. W.; Chesterson, G. J. Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3- substituted derivatives of 2-hydroxypropionanilides. J. Med. Chem., 1988, 31, 954-959.
31. Ebihara, K.; Masuhiro, Y.; Kitamoto, T.; Suzawa, M.; Uematsu, Y.; Ono, T.; Harda, H.; Matsuda, K.; Hasegawa, T.; Masushige, S.; Kato, K.; Mol. Cell. Biol., 1996, 16, 3393.
32. Antunes R.; Batista H.; Srivastava R. M.; Thomas G.; Araujo C. C.; Longo R. L.; Magalhaes H.; Leao M. B.C.; Pavao A. C. Synthesis, characterization and interaction mechanism of new oxadiazolophthalimides as peripheral analgesics. IV. J. Mol. Struct., 2003, 660, 1-13.
33. Heravi, M.M.; Shoar, R.H.; Pedram, L. Synthesis of N-arylphthalimides catalyzed by 1,4-diazabicyclo[2,2,2]octane [DABCO] in solventless system. J. Mol. Catal. A: Chem., 2005, 231, 89-91.
34. Ragavendran, J.V.; Sriram, D.; Patel, S.K.; Reddy, I.V.; Bharathwajan N.; Stables, J.; Yogeeswari, P. Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore. Eur. J. Med. Chem., 2007, 42, 146-151.
35. 2O/EtOH mixtures. Green Chem., 2007, 9, 1067-1072.
36. Worlikar, S.A., Larock, R.C. Palladium-Catalyzed One-Step Synthesis of Isoindole-1,3-diones by Carbonylative Cyclization of o-Halobenzoates and Primary Amines. J. Org. Chem., 2008, 73, 7175-7180.
37. Martin B.; Sekljic H.; Chassaing C. Microwave-Assisted Solid-Phase Synthesis of Phthalimides. Org. Lett., 2003, 5, 1851-1853.
38. 6]. Synth. Commun., 2003, 33, 3777-3780.
39. Le, Z.G.; Chen, Z.C.; Hu, Y.; Zhengd, Q.G. Organic reactions in ionic liquids: Ionic liquid-promoted efficient synthesis of N-alkyl and N-arylphthalimides. Heterocyclic Chem., 2005, 42, 735-737.
40. D'Arcy, P.F.; Griffin, J.P. Thalidomide revisited. Adverse Drug React. Toxicol. Rev., 1994, 13 (2), 65-76.
41. Kumar, S.; Witzig, T.E.; Rajkumar, S.V. Thalidomide as an anticancer agent. J. Cell. Mol. Med., 2002, 160-174.
42. Gershon, D. Finding new uses for thalidomide. Nat. Med., 1995, 1, 1230.
43. Kaplan, G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology. Immunobiology, 1994, 191, 564-568.
44. Black, R.A.; Birde, T.A.; Mohler, K.M. Agents that Block TNF-α Synthesis or Activity. Ann. Rep. Med. Chem., 1997; Vol 32, pp 241-250.
45. Keifer, J.; Guttridge, D. C.; Ashburner, B. P.; Baldwin, A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem., 2001, 276, 22382-22387.
46. Lima, L.M.; Castro, P.; Machado, A.L.; Fraga, C.A.M.; Lugnier, C.; Goncalves de Moraes, V. L.; Barreiroa, E. Synthesis and antiinflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. J. Bioorg. Med. Chem., 2002, 10 3067-3073.
47. Goncalves de Moraes, V. L.; Spinger, M.; Vargaftig, B. B.; Chignard, M. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung Br. J. Pharmacol., 1998, 123, 631-636.
48. Procopio, D. O.; Teixeira, M. M.; Camargo, M. M.; Travassos, L. R.; Ferguson, M. A.; Almeida, I. C.; Gazzinelli, R. T. Differential inhibitory mechanism of cyclic AMP on TNF-α and IL-12 synthesis by macrophages exposed to microbial stimuli. Br. J. Pharmacol., 1999, 127, 1195-1105.
49. Francischi, J. N.; Yokoro, C. M.; Poole, S.; Tafuri, W. L.; Cunha, F. Q.; Teixeira, M. M. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur. J. Pharmacol., 2000, 399, 243-249.
50. Bourguignon, J. J.; Desaubry, L.; Raboisson, P.; Wermuth, C. G.; Lugnier, C. 9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors. J. Med. Chem., 1997, 40, 1768-1770.
51. Alexandre-Moreira, M.S.; Takiya, C.M.; Arruda, L.B.D.; Pascarelli, B.; Gomes, R.N.; Neto, H.C.F.; Lima, L.M.; Barreiro, E. LASSBio-468: a new achiral thalidomide analogue which modulates TNF-α and NO production and inhibits endotoxic shock and arthritis in an animal model. Int. Immunopharmacol., 2005, 5, 485-495.
52. Kroeger, K. M.; Carville, K. S.; Abraham, L. The 308 tumor necrosis factor-α promoter polymorphism effects transcription. J. Mol. Immunol., 1997, 34, 391-399.
53. Karimi, M.; Goldie, L. C.; Ulgiati, D.; Abraham, L. Integration site-specific transcriptional reporter gene analysis using Flp recombinase targeted cell lines. J. Biol. Tech., 2007, 42, 217-224.
54. Li, J.; Zhang, Y.-P.; Kirsner, R. Angiogenesis in wound repair:angiogenic growth factor and the extracellular effacts. Microsc. Res. Tech., 2003, 60, 107-14.
55. Reynolds, L. P.; Grazul-Bilska, A. T.; Redmer, D. A. Angiogenesis in the female reproductive organs: Pathological implications. Int. J. Exp. Pathol., 2002, 83, 151-163.
56. Matter, A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today, 2001, 6, 1005-1024.
57. Bodolay, E.; Koch, A. E.; Kim, J.; Szegedi, Z. J. Cell. Mol. Med., 2002, 6, 357.
58. Noma, H.; Funatsu, H.; Yamashita, H.; Kitano, S.; Mishima, H. K.; Hori, S. Arch. Ophthalmol., 2002, 120, 1075.
59. Fantl, W. J.; Rosenberg, S. Anti-angiogenesis as a Therapeutic Strategy for Cancer. In Annual Reports in Medicinal Chemistry; Doherty, A. M., Ed.; Academic: San Diego, CA, 2000; p. 123.
60. Eriksson, T.; Bjorkman, S.; Hoglund, P. Clinical pharmacology of thalidomide.Eur. J. Clin. Pharmacol., 2001, 57, 365-376.
61. Kruse, F. E.; Joussen, A. M.; Rohrschneider, K.; Becker, M. D.; Volcker, H. E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Archive for Clini. Exp. Ophthalmol, 1998, 236, 461-466.
62. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman. Thalidomide is an inhibitor of angiogenesis.J. Natil. Acad. Sci. U.S.A., 1994, 91, 4082-4085.
63. Kenyon, B. M.; Browne, F.; D'Amato, R. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. J. Exp. Eye Res., 1997, 64, 971-978.
64. Chu, K. C.; Tarone, R. E.; Freeman, H. P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer, 2003, 97, 1507-1516.
65. Harris, R.; Lohr, K. N. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann. Int. Med., 2002, 137, 917-929.
66. Moorselaar, R. J. A.; Voest, E. E. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol. Cell. Endocrinol., 2002, 197, 239-250.
67. Frydenberg, M.; Stricker, P. D.; Kaye, K. W. Lancet, 1997, 349, 1681.
68. Figg, W. D.; Dahut, W.; Duray, P.; Hamilton, M.; Tompkins, A.; Steinberg, S. M.; Jones, E.; Premkumar, A.; Linehan, W. M.; Floeter, M. K.; Chen, C. C.; Dixon, S.; Kohler, D. R.; Kruger, E. A.; Gubish, E.; Pluda, J. M.; Reed, E. Clin. Cancer Res., 2001, 7, 1888.
69. Kok, S.H.L.; Gambari, R. Chui, C.H.; Yuen, M.C.W.; Lin, E.; Wong, R.S.M.; Lau, F.Y. Gregory Cheng, Y.M.; Lam, W.S. Chan, S.H.; Lam, K.H.; Cheng, C.H.; Lai, P.B.S.; Yu, M.W.Y.; Cheung, F.; Tanga, J.C.O.; Chana, A.S.C. Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines. Bioorg. Med. Chem., 2008, 16, 3626-3631.
70. Chan, S.H.; Lam, K.H.; Chui, C.H.; Gambari, R. Yuen, M.C.W.; Wong, R.S.M.; Cheng, G.Y.M.; Lau, F.Y.; Kwok Au, Y. Cheng, C.H.; Lai, P.B.S.; Kan, C.W.; Kok, S.H.L.; Tang, J.C.O.; Chan, A.S.C. The preparation and in vitro antiproliferative activity of phthalimide based ketones on MDAMB-231 and SKHep-1 human carcinoma cell lines. Eur. J. Med. Chem., 2009, 44, 2736-2740.
71. Hashimoto, Y. Structural development of biological response modifiers based on thalidomide. Bioorg. Med. Chem., 2002, 10, 461-479.
72. Schumacher, H.; Smith, R.L.; Williams, R.T. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. Chemother., 1965, 25, 338-351.
73. Georgopoulos, A.; Koch, H.P.; Czejka, M.J. Invitro kinetics and metabolism of R-phthalimido-glutarimide. Int. J. Exp. Clin. Chemother., 1990, 3(3), 135-141.
74. Muller, G.W.; Corral, L.G.; Shire, M. G.; Wang, H. Moreira, A.; Kaplan, G.; Stirling, D.I. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem., 1996, 39, 3238-3240.
75. Zhu, X.; Giordano, T.; Yu, Q.S.; Holloway, H.W.; Perry, T. A.; Lahiri, D. K.; Brossi, A.; Greig, N. H. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-α inhibitory activity. J. Med. Chem., 2003, 46, 5222-5229.
76. Machado, A.L.; Lima, L.M.; Araú jo-Jr, J.X.; Fraga, C.A.M.; Koatzc, V. L.G.; Barreiroa, E. J. Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorg. Med. Chem. Lett., 2005, 15 1169-1172.
77. Stewart, S.G.; Spagnolo, D.; Polomska, M.E.; Sin, M.; Karimib, M.; Abraham L. Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling. Bioorg. Med. Chem. Lett., 2007, 17 5819-5824.
78. Capitosti, S.M.; Hansen, T.; Brown M. Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer. Bioorg. Med. Chem., 2004, 12, 327-336.
79. Bauer, K. S.; Dixon, S. C.; Figg, W. D. Inhibition of Angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol., 1998, 55, 1827-1834.
80. Filler, R.; Kobayashi, Y.; Yagupolskii, L. M.; Eds. Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications; Elsevier: Amsterdam, 1993.
81. Gordon, G. B.; Spielberg, S. P.; Blake, D. A.; Balasubramanian, V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A., 1981, 78, 2545-2548.
82. Noguchi, T.; Fujimoto, H.; Sano, H. Miyajima, A.; Miyachi, H.; Hashimoto, Y. Angiogenesis inhibitors derived from thalidomide. Bioorg. Med. Chem. Lett., 2005, 15, 5509-5513.
83. Lima, M.L.; C. F. de Brito, F. D. de Souza, S.; Miranda, A. L.P.; Rodrigues, C.R.; Fragaa, C.A.M.; Barreiroa, E. J. B. Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorg. Med. Chem. Lett., 2002, 12, 1533-1535.